(ADNT) Adient - Overview
Stock: Seats, Mechanisms, Frames, Foams, Trim
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 63.9% |
| Relative Tail Risk | -6.70% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.06 |
| Alpha | 34.96 |
| Character TTM | |
|---|---|
| Beta | 1.327 |
| Beta Downside | 1.218 |
| Drawdowns 3y | |
|---|---|
| Max DD | 76.92% |
| CAGR/Max DD | -0.19 |
Description: ADNT Adient January 16, 2026
Adient plc (NYSE:ADNT) designs, develops, manufactures, and markets complete seating systems and components-including mechanisms, frames, foams, head restraints, armrests, and trim covers-for passenger cars, commercial vehicles, and light trucks. The company supplies original equipment manufacturers (OEMs) across four geographic regions: North America and South America; Europe, the Middle East, and Africa; and Asia. Incorporated in 2016 and headquartered in Dublin, Ireland, Adient operates as a pure-play automotive seating supplier.
Key operating metrics show FY 2023 revenue of approximately $6.5 billion with an adjusted EBITDA margin near 6%, reflecting modest profitability in a capital-intensive segment. The business is highly sensitive to global vehicle production volumes-an 8% YoY decline in U.S. light-vehicle output in Q4 2023 trimmed order pipelines, while the accelerating rollout of electric vehicles is reshaping seat-architecture demand, prompting Adient to invest in lightweight, modular designs. Additionally, raw-material cost volatility (e.g., foam and steel) and supply-chain disruptions remain material risk factors that can compress margins.
For a deeper quantitative dive, see the ADNT valuation model on ValueRay.
Piotroski VR‑10 (Strict, 0-10) 2.5
| Net Income: -256.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.02 > 0.02 and ΔFCF/TA -0.67 > 1.0 |
| NWC/Revenue: 3.07% < 20% (prev 2.78%; Δ 0.29% < -1%) |
| CFO/TA 0.05 > 3% & CFO 450.0m > Net Income -256.0m |
| Net Debt (1.44b) to EBITDA (384.0m): 3.75 < 3 |
| Current Ratio: 1.12 > 1.5 & < 3 |
| Outstanding Shares: last quarter (81.3m) vs 12m ago -9.77% < -2% |
| Gross Margin: 6.61% > 18% (prev 0.06%; Δ 654.8% > 0.5%) |
| Asset Turnover: 158.8% > 50% (prev 157.1%; Δ 1.73% > 0%) |
| Interest Coverage Ratio: 0.28 > 6 (EBITDA TTM 384.0m / Interest Expense TTM 208.0m) |
Altman Z'' -0.23
| A: 0.05 (Total Current Assets 4.13b - Total Current Liabilities 3.69b) / Total Assets 8.95b |
| B: -0.13 (Retained Earnings -1.17b / Total Assets 8.95b) |
| C: 0.01 (EBIT TTM 59.0m / Avg Total Assets 9.15b) |
| D: -0.17 (Book Value of Equity -1.17b / Total Liabilities 6.80b) |
| Altman-Z'' Score: -0.23 = B |
Beneish M -3.20
| DSRI: 1.00 (Receivables 1.87b/1.90b, Revenue 14.54b/14.69b) |
| GMI: 0.96 (GM 6.61% / 6.32%) |
| AQI: 0.92 (AQ_t 0.38 / AQ_t-1 0.41) |
| SGI: 0.99 (Revenue 14.54b / 14.69b) |
| TATA: -0.08 (NI -256.0m - CFO 450.0m) / TA 8.95b) |
| Beneish M-Score: -3.20 (Cap -4..+1) = AA |
What is the price of ADNT shares?
Over the past week, the price has changed by +27.21%, over one month by +35.41%, over three months by +39.41% and over the past year by +59.49%.
Is ADNT a buy, sell or hold?
- StrongBuy: 2
- Buy: 0
- Hold: 8
- Sell: 1
- StrongSell: 1
What are the forecasts/targets for the ADNT price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 25.1 | -5.3% |
| Analysts Target Price | 25.1 | -5.3% |
| ValueRay Target Price | 28.6 | 8.2% |
ADNT Fundamental Data Overview February 01, 2026
P/S = 0.112
P/B = 0.9334
P/EG = 0.1137
Revenue TTM = 14.54b USD
EBIT TTM = 59.0m USD
EBITDA TTM = 384.0m USD
Long Term Debt = 2.39b USD (from longTermDebt, last quarter)
Short Term Debt = 11.0m USD (from shortTermDebt, last quarter)
Debt = 2.40b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 1.44b USD (from netDebt column, last quarter)
Enterprise Value = 3.07b USD (1.63b + Debt 2.40b - CCE 958.0m)
Interest Coverage Ratio = 0.28 (Ebit TTM 59.0m / Interest Expense TTM 208.0m)
EV/FCF = 14.96x (Enterprise Value 3.07b / FCF TTM 205.0m)
FCF Yield = 6.69% (FCF TTM 205.0m / Enterprise Value 3.07b)
FCF Margin = 1.41% (FCF TTM 205.0m / Revenue TTM 14.54b)
Net Margin = -1.76% (Net Income TTM -256.0m / Revenue TTM 14.54b)
Gross Margin = 6.61% ((Revenue TTM 14.54b - Cost of Revenue TTM 13.57b) / Revenue TTM)
Gross Margin QoQ = 6.70% (prev 6.34%)
Tobins Q-Ratio = 0.34 (Enterprise Value 3.07b / Total Assets 8.95b)
Interest Expense / Debt = 2.25% (Interest Expense 54.0m / Debt 2.40b)
Taxrate = 40.62% (26.0m / 64.0m)
NOPAT = 35.0m (EBIT 59.0m * (1 - 40.62%))
Current Ratio = 1.12 (Total Current Assets 4.13b / Total Current Liabilities 3.69b)
Debt / Equity = 1.36 (Debt 2.40b / totalStockholderEquity, last quarter 1.77b)
Debt / EBITDA = 3.75 (Net Debt 1.44b / EBITDA 384.0m)
Debt / FCF = 7.02 (Net Debt 1.44b / FCF TTM 205.0m)
Total Stockholder Equity = 1.77b (last 4 quarters mean from totalStockholderEquity)
RoA = -2.80% (Net Income -256.0m / Total Assets 8.95b)
RoE = -14.46% (Net Income TTM -256.0m / Total Stockholder Equity 1.77b)
RoCE = 1.42% (EBIT 59.0m / Capital Employed (Equity 1.77b + L.T.Debt 2.39b))
RoIC = 0.84% (NOPAT 35.0m / Invested Capital 4.17b)
WACC = 5.16% (E(1.63b)/V(4.02b) * Re(10.80%) + D(2.40b)/V(4.02b) * Rd(2.25%) * (1-Tc(0.41)))
Discount Rate = 10.80% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -6.53%
[DCF Debug] Terminal Value 83.93% ; FCFF base≈233.8m ; Y1≈189.3m ; Y5≈131.5m
Fair Price DCF = 33.13 (EV 4.03b - Net Debt 1.44b = Equity 2.60b / Shares 78.3m; r=5.90% [WACC]; 5y FCF grow -22.81% → 2.90% )
EPS Correlation: -18.07 | EPS CAGR: 0.88% | SUE: -0.28 | # QB: 0
Revenue Correlation: 15.79 | Revenue CAGR: 1.56% | SUE: 0.78 | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.58 | Chg30d=-0.002 | Revisions Net=+0 | Analysts=10
EPS current Year (2026-09-30): EPS=2.02 | Chg30d=+0.073 | Revisions Net=+6 | Growth EPS=+4.6% | Growth Revenue=-0.1%
EPS next Year (2027-09-30): EPS=3.04 | Chg30d=+0.044 | Revisions Net=+2 | Growth EPS=+50.6% | Growth Revenue=+2.4%